Skip to main content
. Author manuscript; available in PMC: 2022 Apr 13.
Published in final edited form as: Immunity. 2021 Mar 10;54(4):829–844.e5. doi: 10.1016/j.immuni.2021.02.018

Figure 6. CAR T cells exhibit an analogous transient early activated program upon infusion into advanced non-Hodgkin Lymphoma patients.

Figure 6

(A) Axicabtagene ciloleucel chimeric antigen receptor T cells from two advanced non-Hodgkin Lymphoma patients were sampled at the time of infusion, and PBMCs were isolated from the same patients on days 7, 14, 21, 28 and month 3 post-infusion for analysis by mass cytometry. (B) Pooled CD8+ CAR T cells from all time points post-infusion visualized by a force-directed graph. (C) Expression levels of key metabolic markers by CAR T cells at each time point post-infusion by patient. (D) Spearman correlation matrix of CAR T cells at time of infusion (D0) into advanced lymphoma patients. (E) ICOS expression in individual patients at each time point post-infusion represented by histograms.